By Jami Koziel, RRT, CPFT
Pulmonary Services, Blanchard Valley Health System
Asthma is a heterogeneous respiratory disease–meaning it presents in many different ways–that affects an estimated 25 million Americans, with six million being children. The financial cost of asthma exceeds $81 billion every year and despite all the resources invested, asthma is responsible for over 3,500 deaths annually in the United States. The prevalence of asthma is proven to be higher among individuals of low socioeconomic status than among those with higher socioeconomic status.
Generally, there has been a lack of priority in the effects and differences in asthma prevalence among populations as well as the response to therapies among racial and ethnic minorities. To illustrate, African American patients respond differently to corticosteroids in contrast with White patients. One study suggests Hispanic and non-Hispanic White children exhibit better responses to increasing therapy with Long-Acting Beta Agonist (LABA), rather than higher doses of Inhaled Corticosteroids (ICS), whereas African American children were less likely to respond to adding leukotriene receptor antagonists, and more likely to respond to increasing dosing of ICS.
